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a b s t r a c t
Typhoid fever is estimated to cause between 11.9–26.9 million infections globally each year with
129,000–216,510 deaths. Access to improved water sources have reduced disease incidence in parts of
the world but the use of efficacious vaccines is seen as an important public health tool for countries with
a high disease burden.
A new generation of Vi typhoid conjugate vaccines (TCVs), licensed for use in young children and
expected to provide longer lasting protection than previous vaccines, are now available. The WHO
Strategic Advisory Group of Experts on Immunization (SAGE) has convened a working group to review
the evidence on TCVs and produce an updated WHO position paper for all typhoid vaccines in 2018 that
will inform Gavi, the Vaccine Alliance’s future vaccine investment strategies for TCVs.
The Typhoid Vaccine Acceleration Consortium (TyVAC) has been formed through a $36.9 million fund-
ing program from the Bill & Melinda Gates Foundation to accelerate the introduction of TCVs into Gavi-
eligible countries.
http://dx.doi.org/10.1016/j.vaccine.2017.08.001
 2018 Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
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In October 2016, a meeting was held to initiate planning of TCV effectiveness studies that will provide
the data required by policy makers and stakeholders to support decisions on TCV use in countries with a
high typhoid burden.
Discussion topics included (1) the latest evidence and data gaps in typhoid epidemiology; (2) WHO and
Gavimethods and data requirements; (3) data on TCV efficacy; (4) cost effectiveness analysis for TCVs from
mathematicalmodels; (5) TCVdelivery andeffectiveness studydesign. Specifically, participantswere asked
to comment on study design in 3 sites for which population-based typhoid surveillance is underway.
The conclusion of the meeting was that country-level decision making would best be informed by the
respective selected sites in Africa and Asia vaccinating children aged from 9-months to 15-years-old,
employing either an individual or cluster randomized designwith design influenced by population charac-
teristics, transmission dynamics, and statistical considerations.
 2018 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
1. Introduction
Typhoid fever is estimated to cause between 11.9 million-26.9
million cases and 129,000–216,510 deaths annually [1–3]. The bur-
den of disease is largely within low- and middle-income countries
primarily throughout Asia and Africa [4,5]. Whilst improvements
in drinking water quality have been successful in reducing rates
of typhoid fever in certain parts of the world [6–8], control has
been hampered elsewhere and typhoid remains a significant public
health problem [1,3].
In 2008 the World Health Organization (WHO) recommended
the consideration of two licensed typhoid vaccines (Vi-
polysaccharide and Ty21a), for programmatic use by countries
with high rates of typhoid fever for controlling endemic disease,
as well as for use in outbreak settings and for travelers to endemic
areas [9]. However, with the expectation of second generation
typhoid conjugate vaccines (TCV) becoming available in the near
future Gavi, the Vaccine Alliance, deferred decisions on funding
support until TCVs were licensed and prequalified byWHO [10,11].
Two Vi tetanus toxoid conjugate vaccines have now been
licensed in India, with one manufacturer (Bharat Biotech) applying
for WHO prequalification [12,13]. Due to these developments, the
WHO Strategic Advisory Group of Experts on Immunization (SAGE)
has convened aworking group to ‘review the scientific evidence and
relevant programmatic considerations to formulate updated recom-
mendations on the use of typhoid vaccines’ [14]. Specific considera-
tion will be given to estimates of disease burden, vaccine schedules,
and economic analyses of vaccination programs. Publication of an
updated WHO position paper on typhoid vaccines is scheduled for
2018 [14]. These recommendations will be highly relevant to Gavi,
given their prior positive statements on support for TCV.
At this key stage in typhoid vaccine development, the Bill &
Melinda Gates Foundation (BMGF) published a request for propos-
als to accelerate the introduction of TCVs into Gavi-eligible coun-
tries and to contribute to the data to support the use of TCVs as
means of reducing the global typhoid burden. With $36.9M from
BMGF, the Typhoid Vaccine Acceleration Consortium (TyVAC)
was formed in 2016 comprising core partners at the University of
Maryland’s Center for Vaccine Development, the University of
Oxford’s Oxford Vaccine Group and PATH to achieve this goal [15].
A meeting of key stakeholders was held in Oxford, UK in Octo-
ber 2016 to discuss some of the critical issues surrounding typhoid
fever and the impact on TCV effectiveness study design.
2. Typhoid vaccine acceleration consortium
In her introductory remarks, Dr. Anita Zaidi, Director of Enteric
Diseases at BMGF, highlighted the motivations for this program on
behalf of the foundation. Firstly, typhoid fever is primarily a dis-
ease of the poor which will require coordinated public health inter-
ventions to prevent and with the rising concern of antimicrobial
drug resistance the global situation may yet get worse [16]. Sec-
ondly, with the recent development of TCVs the case for global
typhoid control is compelling and there may be opportunity to
demonstrate a dramatic impact through vaccination.
Following this the Director of TyVAC, Professor Kathleen Neuzil,
outlined some of the key objectives for the consortium;
 To serve as a coordinating body for typhoid-related research
and control activities
 To foster supportive global policies
 To ensure typhoid and TCVs are recognized as global, regional
and national health priorities
 To provide data on impact, effectiveness, appropriate vaccine
strategies and cost of TCV use
 To support countries in decision-making and preparation for
sustained TCV introduction
Dr. Neuzil also reviewed lessons learned from other successful
vaccine introduction efforts, and the need for clear goals and stake-
holder involvement. Further, as TCVs are licensed, the goal of these
studies will be to inform policy and financing decisions – thus the
studies must be designed in light of that goal. Current funding only
allows these studies to be done in a limited number of settings.
Therefore, we must ensure that these settings and designs are suf-
ficiently generalizable to inform non-trial countries in translating
results to their local settings.
3. WHO perspectives
Understanding the data required byWHO to recommend TCVs is
an important consideration for the consortium. Two central policy
issues are currently under review by the WHO, (1) should TCV be
recommended over Vi-polysaccharide (ViPS) and Ty21a vaccines
for use in persons 2 years of age and older? (2) should TCVbe recom-
mended for routine use in children <2 years of age and what should
be the lower age limit for use in this group?Recent ad-hocWHOcon-
sultations to discuss the initiationof a SAGEpolicy pathway for TCVs
identified multiple gaps in the data required to inform these policy
decisions (Table 1). The design of TCV effectiveness studies should
bemadewith these specific data gaps inmind, to provide the critical
data that policy makers at global, regional and country levels will
require to adopt and promote these new vaccines.
The SAGE Working Group on Typhoid Vaccines’ review of the
data to support TCV use will lead to consideration by SAGE for pol-
icy recommendations in October 2017.
4. Gavi
Understanding data used by Gavi before investing in TCV intro-
duction is an important consideration for the consortium. In 2008,
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Gavi instituted a new method to identify vaccines that would be
supported in Gavi-eligible countries. In order to evaluate each vac-
cine in the same objective manner, Gavi proposed evaluation indi-
cators including overall health impact (e.g., childhood mortality,
all-age mortality/morbidity); other vaccine impact considerations
(e.g., potential to stop epidemics, indirect protection [‘‘herd immu-
nity”]), implementation feasibility (including ease of program-
matic integration) and cost-effectiveness. In the future, long-term
morbidity, equity, and overall affordability may feature promi-
nently in Gavi investment decisions. Many of these evaluation
indicators will benefit from the availability of vaccine effectiveness
study data.
Gavi has previously considered typhoid vaccine support.
Despite a 2007 SAGE recommendation of live, oral Ty21a vaccine
(3–4 dose schedule) and injectable ViPS vaccine (single dose sched-
ule) by typhoid-endemic countries [9], with the expectation of
near-term TCV availability, a 2008 Gavi Vaccine Investment Strat-
egy (VIS) Working Group recommended that Gavi should not
invest in typhoid vaccination in its 2009–13 VIS. This working
group cited the limited duration of protection given by the Ty21a
and ViPS vaccines that would necessitate re-vaccination every
3 years and the inability to use these vaccines in children less than
2 years of age as important limitations of those vaccines. In 2008,
Gavi expressed a strong preference for TCVs which could theoret-
ically be administered through routine vaccination of infants as
part of a national immunization schedule following catch-up
campaigns.
At this time, it is not known if Gavi will consider TCV support
based on the 2009–2013 VIS or whether it will need to be consid-
ered in new discussions related to the 2019–2023 VIS. Although
this is not known, the consortium discussed the importance of trial
design, campaign strategy, and types of data that are collected to
inform VIS working groups.
Whilst providing data to support a Gavi investment is impor-
tant, it is also important to consider data needed to inform intro-
duction decisions by countries that are not eligible for Gavi
support. Engaging with country-level policymakers will help the
consortium understand perceived need for typhoid vaccinations
and identify the data needed by lower middle-income countries
to support the introduction of TCVs. Policymaker surveys con-
ducted as part of the Disease of Most Impoverished (DOMI) pro-
gram identified that typhoid vaccine introduction would be best
facilitated with country-specific disease burden data, efficacy stud-
ies in local populations and evidence of potential economic savings
from vaccination [17].
5. Burden of disease
Precise estimates of the global burden of disease are difficult to
establish owing to the non-specific presentation of disease, the
lack of reliable diagnostic facilities in many regions, and the insen-
sitivity of commonly used diagnostic tests [18]. Additionally, the
burden of typhoid disease can fluctuate widely depending on geo-
graphic context and the occurrence of epidemics. Currently it is
estimated that typhoid fever is responsible for between 11.9
million-26.9 million cases and 129,000–216,510 deaths annually
[1–3,19,5].
Burden of disease studies performed to date have shown high
rates of typhoid fever throughout South and South East Asia.
Within these high-burden regions, the epidemiology of typhoid is
complicated by marked inter- and intra-country variation. For
example, data from the DOMI program highlighted incidence rates
varying from 24.2/100,000 in Vietnam, to 493.5/100,000 in India
(per 100,000 person-years) [20]. Surveillance throughout Asia has
predominantly been undertaken in urban centers with consistently
high rates of disease [21–24], but less is known about the rates of
disease in rural areas [8].
Historically, there has been less information available regarding
disease epidemiology in Africa [19]. Fewer studies have been con-
ducted and the heterogeneity of disease may be higher [25].
Surveillance performed in two sites in Kenya between 2006 and
2009 found that the incidence of blood-culture proven typhoid
fever in rural and urban sites varied from 29 up to 247 cases per
100,000 person-years of observation (PYO), although these are
crude rates [26]. Recent data from the Typhoid Fever Surveillance
in Africa Program (TSAP) [27] highlighted marked differences in
incidence rates between sites in Africa with adjusted rates ranging
from 0 in Sudan to 383 per 100,000 PYO in Burkina Faso [28]. This
study also demonstrated marked intra-country variation with
higher rates in rural Ghana compared with an urban setting [29].
The uncertain global disease burden of typhoid fever presents
several challenges. Firstly, conclusions drawn from vaccine effec-
tiveness studies need to be generalizable to different epidemiolog-
ical contexts, so that individual countries can make informed
decisions on vaccine introduction. With the heterogeneity of dis-
ease between and within countries, policy makers will require
applicable data for their context.
Secondly, the design of any effectiveness trial must be robust
enough to provide accurate data despite unpredictable rates of dis-
ease. This has a direct impact on the design of any trial as data will
need to be analyzed concurrently in the intervention and control
Table 1
Proposed data gaps for near-to-medium term research agenda to guide TCV policy and use (Used with permission from WHO; TCV Data Gaps Meeting Report September 2015
http://www.who.int/immunization/research/meetings_workshops/typhoid_conjugate_vaccine_sept15/en/).
Critical 1–3 year research agenda Critical 1–3 year research agenda Critical 2–5 year research agenda
Evidence generation Vaccine development Typhoid fever control strategies
1. Surveillance projects using standardized methodology
(e.g., SETAa, SEAPb) – ongoing
2. Disease transmission and carriage – ongoing
3. Cost-effectiveness analysis and modelling – ongoing
4. Diagnostics – different types (Point-of- care, surveillance,
environmental)
1. Assay & reagents development and standard-
ization – immediate
2. Oxford University Controlled Human Infec-
tions Models – ongoing
3. Clinical trial endpoints/study design for new
vaccines - immediate
4. WHO global consensus on the requirements
for licensure
5. WHO global reference laboratories and
reagents
1. Integration with new WaSHc initiatives
2. Achievement of control and prevention in
targeted communities
3. Need new vaccines to achieve licensure
4. Vaccine immunization strategies and
schedules
5. Environmental surveillance
a Severe Typhoid in Africa Program.
b Surveillance of Enteric Fever in Asia Project.
c Water, Sanitation and Hygiene.
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arm to minimize the bias produced by any significant change in
incidence over time. Finally, disease burden and severity estimates
are important to policy makers when considering cost-
effectiveness analyses and cases/deaths averted [30].
6. Site-specific data
Specifically, for TyVAC, three sites (See interactive maps for
Dhaka, Bangladesh; Kathmandu, Nepal and Blantyre, Malawi) had
been evaluated prior to this meeting in which to conduct planned
vaccine effectiveness studies. Each site is currently conducting
detailed disease burden studies as part of the STRATAA program
[31] (Supplemental Table 2), which could be leveraged for these
planned studies. As such, there will be recent epidemiological data
on the incidence of blood culture confirmed typhoid fever, as well
as rates of sub-clinical infection identified by serosurveillance and
the likely prevalence of chronic carriers in all three sites.
7. Efficacy of TCVs
Proof-in-principle of TCV efficacy is derived from trials of the US
NIH Vi-rEPA vaccine, and data from these trials were reviewed to
inform future trial designs. Efficacy of up to 92% at 24 months
and 89% at 46 months has been demonstrated in trials of the Vi-
rEPA vaccine carried out in Vietnam, when given as a two-dose
schedule in 2–5 year olds [32,33]. A post hoc analysis of trial par-
ticipants administered a single dose of the Vi-rEPA vaccine indi-
cated a protective efficacy of approximately 88% [34]. However,
these trials do not address the issues of TCV efficacy in children
under the age of 2 years.
Whilst efficacy data are available for Vi-rEPA, it is unclear
whether similar results would be observed with TCVs that use
other carrier proteins, such as tetanus toxoid. Immuno-bridging
from the Vi-rEPA studies would be possible in an ideal situation,
and efforts to standardize assays to compare products are ongoing.
Several TCVs are currently in development, including Vi-CRM197
and Vi-diptheria toxoid conjugates, many of which are in Phase 1
and 2 trials [35,13]. There are currently two Vi-tetanus toxoid con-
jugates licensed on the basis of immunogenicity. One such vaccine,
PedaTyphTM (a Vi-polysaccharide tetanus toxoid conjugate manu-
factured by Bio-Med) has been trialed in a school-based cluster
randomized study in an urban slum setting of Kolkata, India,
although published data are currently limited in size to allow for
firm conclusions [12].
Clinical and immunogenicity data on the other tetanus-
conjugate Vi vaccine Typbar-TCV was presented by Bharat
Biotech. Typbar-TCV is the first TCV to be submitted for prequal-
ification by WHO. Immunogenicity data were derived from a phase
3 study, comprising an open label arm of 327 children aged
6 months to 2 years, and a randomized control arm of 654 individ-
uals aged 2–45 years who received either Typbar-TCV or a com-
parator Vi-polysaccharide vaccine (Typbar Vi). In these studies,
Typbar-TCV induced consistently higher anti-Vi IgG responses
than Vi-polysaccharide (anti-Vi IgG 1292–1937 EU/ml Typbar-
TCV vs. 411 EU/ml Typbar Vi) and was noted to be immunogenic
in children aged under 2 years. The avidity of anti-Vi IgG following
Typbar-TCV vaccination was increased compared with that follow-
ing Typbar-Vi vaccination. Long term immunogenicity data are
available for between three to five years post vaccination, which
indicate long term persistence of anti-Vi [13].
8. Cost-effectiveness
A major aim of the TyVAC programwill be to generate measures
of cost-effectiveness within the study sites that could be scaled up
to aid future country-level decisions on TCV introduction. The con-
sortium includes a group of health economics specialists who will
engage at an early stage with the aim of tailoring trial design to
capture relevant economic data to undertake a prospective cost-
effectiveness analysis.
Currently unpublished modelling data were presented to
review the predicted cost-effectiveness of TCVs across different
settings with different epidemiological and health-economic char-
acteristics. Routine vaccination at 9 months of age was predicted to
result in a substantial decline in disease incidence at all sites, with
an additional benefit of catch-up campaigns, both in terms of dis-
ease incidence and disability adjusted life years (DALYs) averted.
When viewed from a healthcare provider perspective, routine
vaccination alone at 9 months of age was predicted to be ‘‘cost-
effective”, ‘‘very cost effective” or ‘‘cost saving” in most of the set-
tings modelled, with the exception of areas with low incidence of
disease and low cost of illness. Additional cost-effectiveness bene-
fits were predicted to be achieved by one-time catch up campaigns
– including routine vaccination at 9 months with catch up to the
age of 5 years, 15 years, 25 years or to include all ages.
To undertake a prospective cost-effectiveness analysis, eco-
nomic endpoints should be included as secondary objectives of
effectiveness trials. The cost-effectiveness models presented pri-
marily considered healthcare provider costs, rather than individual
and societal costs resulting from typhoid infection. In part, this
results from the absence of empirical economic data on these
potentially important metrics. It was recognized that within the
context of a trial, data on patient-level expenditure and health uti-
lization could be collected with relatively limited additional effort
using a well-designed case report form. Such data could subse-
quently be assigned monetary costs that form the basis of cost-
effectiveness analyses and improved modelling estimates.
9. Vaccine delivery strategies
The meeting considered a range of different vaccine delivery
strategies, which could be applied either in an effectiveness trial
or to provide evidence for future programmatic use. It was recog-
nized that there are distinct benefits and limitations of each deliv-
ery strategy, which must be balanced against overall feasibility and
the need to fill specific data gaps.
9.1. Mass vaccination
A strategy of routine vaccination starting at 9 months of age and
mass vaccination of the population at risk, with no upper age limit,
was discussed by the meeting attendees. This approach is likely to
be themost impactful strategy, particularly in terms of direct effects
of TCVs aswell as indirect effects. Amass-vaccination strategy could
be a test of the feasibility of eventual disease elimination in a con-
fined area and would increase the likelihood for vaccination of
high-risk groups, including food handlers, non-immune adults from
non-endemic areasmoving into endemic areas aswell as thosewith
medical co-morbidities. It is unknownwhether countries can afford
this approach or external donors such as Gavi will support it.
9.2. EPI vaccination plus catch-up campaigns
Multiple variations of a delivery strategy incorporating TCVs
into the routine childhood (‘‘EPI”) vaccination schedule with a con-
comitant catch-up campaign were discussed. The proposed catch-
up campaigns could be used in individuals up to 5 years, 15 years
or 45 years of age, as outlined in modelling studies.
Such a strategy is the most likely platform for post-study use in
endemic countries. Introduction of TCVs into the existing EPI
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schedule is anticipated to result in high vaccine coverage, as was
seen with similar catch-up campaigns for other vaccines (e.g.
MenAfrivac). Whilst this approach may result in a less pronounced
effect on disease burden compared with a mass vaccination cam-
paign discussed above, this might be balanced by increased
feasibility.
9.3. School-based vaccination
Vaccination of school-age children (defined as those aged 5–
15 years) was also considered as a delivery strategy. An advantage
of this approach is that it is a convenient group to access and
achieve high coverage depending on the proportion of children in
high risk age groups who attend school in the target population.
Indirect vaccine effects could also be estimated, particularly in
those aged under 2 years, by measuring transmission within
households of vaccinated school children.
The cost of delivery of a school-based campaign might be high
comparing with integration within the EPI schedule. School-
based vaccination strategies could also raise issues of equity, either
by missing children not enrolled in schools due to economic issues
or gender imbalance, and would require engagement with both
public and private school systems.
10. Trial design
The performance of TCVs could, in theory, be studied using sev-
eral different trial designs, each with a distinct set of benefits and
limitations. Competing priorities to be addressed through these tri-
als include the desire to inform financing decisions; define the
extent of indirect protection conferred by TCVs; define efficacy in
children under 2 years of age; or, simply, feasibility.
Data describing TCV immunogenicity and efficacy has already
been published for certain settings [12,13,36].What is now required
for policy makers are effectiveness studies, performed in ordinary
conditions providing real-world data on both the protection pro-
vided by a vaccine and also the practicalities of implementation.
General issues included the need to design an ethical, unbiased
trial which is acceptable to the population at study sites. Blinding
of both participants and study staff was identified as a key question
to consider, in particular with regards to ascertainment of cases
during the follow up period after vaccination, as knowledge of vac-
cination status might affect care-seeking, or risk-taking behaviour.
It was recognized that different trial designs might be more, or
less, appropriate for different study sites. However, introducing
different trial designs, or target populations to be enrolled, risks
complicating cross-site conclusions as evidenced through the
divergent findings generated by cluster randomized trials of ViPS
vaccine in Kolkata and Karachi [37,38,49].
Observational studies were rejected as means of evaluating TCV
impact due to the high risk of bias with a disease like typhoid
because of its epidemic potential and seasonal variation. Whilst
no single trial design received unanimous support, the strengths
and weaknesses of four designs were proposed to answer the
specific questions related to typhoid fever vaccination.
10.1. Individual randomization
In an individually randomized control trial, participants would
be randomly allocated to receive either TCV or control vaccine.
Large scale, individually randomized controlled trials have been
used to determine efficacy of conjugate vaccines for Hib and pneu-
mococcal disease [39,40], as well as for typhoid fever. [32,33] Such
a trial design offers several advantages, including feasibility and
smaller sample size requirements, compared with other trial
designs discussed below. Importantly, an individually randomized
trial could be used to determine the direct efficacy of TCVs in chil-
dren under 2 years of age, which has been identified as a major
knowledge gap. The estimate of direct efficacy would be indepen-
dent of herd effects, which might vary depending on geographic
setting or the age-group targeted. A major drawback of this
approach is that an individually randomized trial would not gener-
ate data on indirect and overall protection of TCVs.
10.2. Cluster randomized control trials
In a cluster randomized trial (CRT), population-based clusters
would be defined and randomized to receive either the interven-
tion vaccine or control vaccine. In this design, a percentage of each
individual cluster would be vaccinated, and total protection
assessed by comparing the incidence of disease in vaccinated indi-
viduals in the vaccinated arm, compared with those who received
the control vaccine in control clusters. This design was successfully
applied in two large trials of ViPS vaccine in Karachi and Kolkata as
part of the DOMI program [37,38,41]. In a separately funded study,
plans are underway to evaluate effectiveness of TCV for a public-
sector implementation group using a cluster randomized approach
in NaviMumbai, India. (Personal communication with CDC.)
One of the main strengths of CRTs is the capacity to produce
data on total as well as indirect and overall protection of TCVs
under blinded conditions. It, arguably, is more reflective of a
‘real-world’ situation, than an individually randomized study,
where less than 100% of a population will be vaccinated and herd
protection can be measured.
Drawbacks of the CRT approach include the need for a larger
sample size than an individually randomized study design. With
the CRT design, there is a risk of ‘contamination’ between clusters
by movement of persons into, out of, or between clusters. The pro-
posed study sites represent densely populated urban areas with
high levels of migration and population mixing between clusters,
which could reduce all effectiveness estimates. The risk of ‘‘con-
tamination” could be mitigated either by incorporating geographic
‘‘buffer zones” between clusters or by performing surveillance and
analysis of the inner area of a cluster only (the so-called ‘fried-egg’
design).
10.3. Step wedge
The step-wedge trial (STW) design represents a type of cluster-
randomized trial. In a STW [42] instead of randomization by geo-
graphic region as in a cluster randomized control trial, the time
of intervention within each cluster is randomized. Clusters are
phased in for vaccination in a random order at regular intervals,
such that by the end of the study all clusters have crossed over.
Vaccine effectiveness is assessed through comparison of the inci-
dence in clusters already vaccinated versus those not yet phased
in [43]. One proposed advantage of SWTs is the need for smaller
sample sizes to demonstrate impact, as each cluster acts as its
own control [44]. However, it was noted that a step wedge repre-
sents a poorly controlled and usually underpowered CRT. In both
step-wedge designs and CRT, there is a need to consider seasonal-
ity and potential epidemics from point sources, to avoid an accu-
mulation of cases in one cluster or on one side of the ‘wedge’. It
is likely these reasons have played a role in SWTs rarely being used
for vaccine evaluations [43,45].
10.4. Ring vaccination
In a ring-vaccination study, an index positive case would be
identified by the vaccination team, who would proceed to identify
contacts, and contacts of contacts in a cluster. Individuals within
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the single cluster, or the entire cluster, could be randomized to
either the active vaccine or a control with the aim of interrupting
the transmission cycle. Both groups would be under follow-up
for signs of clinical disease [46]. Recent experience of this trial
design, taken from the West African Ebola outbreak, was given
[47].
The major role of a ring-vaccination approach would be in the
measurement of TCV effectiveness in the context of a typhoid epi-
demic. Such an approach might, theoretically, be relevant for test-
ing typhoid vaccines in settings such as in Fiji, where typhoid
frequently occurs in multiple small outbreaks [48]. The predicted
high-incidence of cases in each ring around an identified index case
reduces the overall sample size requirements compared with other
designs. Perhaps the major drawback of the ring-vaccination
approach for typhoid relates to uncertainties surrounding disease
transmission. If, typhoid transmission is via the long-cycle route,
contacts of cases have likely already been exposed to the same
environmental source, or don’t share the same risk factors as the
cases [49,50].
A general consensus at the meeting was reached recommending
a cluster randomized trial design, if feasible, to capture both total
and overall effects with vaccination starting at 9 months of age
and a catch up campaign to 15 years of age. Whist the modeling
data suggested that vaccination up to the age of 45 years is likely
to have the largest impact and remain cost-effective, this approach
is unlikely to be feasible nor affordable within the context of the
trials. It would also be less likely to be supported by financing
agencies or individual governments. A nested immunogenicity
study with individual randomization in the under 2-year age group
was also considered.
11. WASH considerations
TCV effectiveness studies will be undertaken in the context of
ongoing water, sanitation and hygiene (WASH) interventions,
which might lead to a significant reduction in typhoid disease inci-
dence independent of vaccines. This presents two risks to a typhoid
vaccine trial. Firstly, a trial with a small geographic footprint may
be undermined by improvements in water supply during the pro-
cess of the trial. Secondly, the perception of local residents that
what is actually required is not vaccines but improvements to
infrastructure may affect enrollment and community acceptance.
Mitigation of these risks could be possible through surveillance
over a large geographic area and inclusion of a water intervention
into an arm of the trial. The focus of this particular program how-
ever is on vaccine effectiveness, and introducing water improve-
ment was deemed beyond the scope of the planned trials as well
as potentially confounding results.
12. Measuring outcomes
The selection of robust outcome measures will be central to the
design of TCV effectiveness studies. The outcome recorded due to
the vaccination will affect the generalizability of data generated.
Whilst there is no perfect outcome measure, some have clear
advantages.
The primary outcome of TCV effectiveness studies should be to
measure the impact on the burden of typhoid disease using the
incidence of blood-culture positive cases as a fixed endpoint.
Clinically defined endpoints are problematic due to the non-
specific case presentation of typhoid and range of alternate diag-
noses [48–51]. A careful clinical case definition for enrolment
and collection of blood cultures will have to be defined. Explora-
tory diagnostics (e.g. antibody in lymphocyte supernatant (ALS),
culture-PCR) could be used to broaden the case-definition in some
cases, as secondary/exploratory endpoints.
Surveillance at the community level may increase the detection
rate of uncomplicated disease and therefore an increased burden,
but measuring severe disease averted, intestinal perforation, or
hospitalization, for example [52], may be more impactful. With
non-specific outcomes, all-cause mortality is unlikely to be attain-
able to measure with the relatively low mortality rate associated
with typhoid requiring a large sample size. Impact could be seen,
however, with a reduction in hospital febrile admission or outpa-
tient visits, antimicrobial usage or change in antimicrobial resis-
tance patterns. Where clinical outcomes have been used to
measure vaccine preventable disease incidence, much higher esti-
mates of impact have been described [53]. In pneumococcal conju-
gate vaccine studies, for example, a 10-fold increase in impact was
observed when non-specific clinical outcomes were measured
rather than an etiology-confirmed endpoint [40]. In the context
of typhoid fever where blood culture is estimated to be between
50–75% sensitive [18], there will be a significant proportion of
vaccine-preventable but non-etiologically-confirmable disease;
therefore, measuring non-specific outcomes could be an important
factor to build into the program.
13. Conclusion
Typhoid is an important cause of morbidity and mortality in
low resource settings. There is an opportunity now to advance
the use of newly available conjugate vaccines. Through TyVAC,
key stakeholders are now engaged in the process of designing
and implementing trials in 3 settings. These trials should comple-
ment other important initiatives, such as the planned Navi-
Mumbai government introduction in India.
Through the discussions at this meeting, an approach using
either a cluster or individually randomized control strategy start-
ing vaccination at 9 months old with a catch-up campaign to
15 years of age has been proposed using a comparator vaccine in
the control group. Surveillance for a primary outcome of blood-
culture proven typhoid fever, and a broad range of non-specific
secondary outcomes will be performed in 3–4 sites over a period
of two years.
The use of typhoid vaccines to control typhoid in those regions
with the greatest burden could now be a real possibility. This con-
sortium has been created to realize that aim.
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